<DOC>
	<DOCNO>NCT00881140</DOCNO>
	<brief_summary>The purpose study evaluate effect daily dosage vaginally mifepristone reduction uterine fibroid size symptom associate uterine fibroid .</brief_summary>
	<brief_title>Efficacy Study Vaginal Mifepristone Treat Uterine Fibroids</brief_title>
	<detailed_description>Uterine fibroid benign tumor uterus make smooth muscle extracellular matrix protein Collagen Elastin . They exceptionally common ; cumulative incidence diagnosis fibroid woman age 25 45 approximately 30 percent . Uterine fibroid cause abnormal uterine bleeding , dysmenorrhea , low back pain non-cyclic pelvic pain . They also contribute symptom related enlarge pelvic mass ( e.g. , urinary frequency constipation ) . Uterine fibroid also associate increase risk complication pregnancy , infertility , although unclear whether association causative . Symptoms associate uterine fibroid significant impact quality life , score standard measure comparable major chronic disease</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Uninterested fertility study . Premenopausal status . Active symptom related uterine fibroid . Subjects obligate use non hormonal contraceptive study . Abnormal liver renal function Participants significant increase uterine fibroid size short time . Exclusionary health problem contraindicate mifepristone include adrenal disease ; sickle cell anemia ; severe liver , respiratory , renal disease ; blood clotting defect . Current use steroid , anticoagulant , herbal , botanical possible hormonal effect .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>53 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>oral mifepristone</keyword>
	<keyword>vaginal tablet</keyword>
</DOC>